巴黎——法国初创公司Bioptimus,一家专注于利用人工智能技术革新生物科学基础模型的新兴企业,近期成功完成了3500万美元的种子轮融资。这一显著的成绩在其成立仅数月后就已达成,彰显了投资者对其潜力的极大信心。

本轮融资由法国知名生命科学风投公司Sofinnova Partners和公共银行Bpifrance Large Ventures共同领投,显示出业界对Bioptimus愿景的强烈支持。此外,还包括了法国风险投资公司Frst、国际投资机构Cathay Innovation,以及来自美国的投资者Headline、Owkin,以及知名亿万富翁企业家Xavier Niel的积极参与。

Bioptimus致力于构建一个大规模的语言模型,以推动生物技术领域的研究和应用。通过结合人工智能的力量,该公司有望加速对生命科学的理解,为新药研发、疾病治疗及生物技术的其他前沿领域带来革命性的变化。

Sifted的报道指出,这笔资金将用于进一步开发Bioptimus的AI技术,扩大其研发团队,并加速其创新解决方案的市场推广。这一融资事件标志着生物科学与人工智能融合的又一重要里程碑,预示着生物技术行业的未来将更加智能化和高效。

随着全球范围内对生物技术和人工智能的关注度不断提升,Bioptimus的迅速崛起无疑为该领域的创新注入了新的活力。公司创始人表示,他们期待与投资者们共同努力,解锁生物科学的新边界,为人类健康和福祉带来实质性的进步。

英语如下:

News Title: “Bioptimus Rakes in $35M Seed Funding: AI-Powered Biotech Pioneer Sets New Wave”

Keywords: Bioptimus, seed round, nine-figure funding

News Content:

Paris – Bioptimus, a fledgling French startup focusing on revolutionizing biological science models with artificial intelligence, has secured a remarkable $35 million seed funding round. This achievement, accomplished mere months after inception, underscores investors’ high confidence in the company’s potential.

The financing round was co-led by prominent life science venture capital firm Sofinnova Partners and public bank Bpifrance Large Ventures, indicating strong endorsement of Bioptimus’s vision. Other participants include French venture capital firm Frst, international investor Cathay Innovation, and notable involvement from Headline, Owkin, and tech billionaire Xavier Niel from the United States.

Dedicated to building a large-scale language model to propel research and applications in biotechnology, Bioptimus aims to harness AI’s power, accelerating the understanding of life sciences and potentially revolutionizing drug discovery, disease treatments, and other cutting-edge areas within the field.

As reported by Sifted, the funds will be allocated to further develop Bioptimus’s AI capabilities, expand its R&D team, and hasten the market penetration of its innovative solutions. This financing milestone signals another significant integration of biotech and AI, foreshadowing a smarter and more efficient future for the biotechnology industry.

With growing global interest in both biotechnology and AI, Bioptimus’s swift ascent energizes innovation in the sector. The company founders express their excitement to collaborate with investors, striving to unlock new frontiers in biological science and make tangible advancements in human health and well-being.

【来源】https://sifted.eu/articles/bioptimus-owkin-35m-seed

Views: 1

发表回复

您的电子邮箱地址不会被公开。 必填项已用 * 标注